Evidence map›Paper›PMID 24629635›Full record

Trial reportTuberculosis (Edinburgh, Scotland)2014

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Payam Nahid, Erin Bliven-Sizemore, Leah G Jarlsberg, Mary A De Groote, John L Johnson, Grace Muzanyi, Melissa Engle, Marc Weiner, Nebojsa Janjic, David G Sterling and 1 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Tuberculosis (Edinburgh, Scotland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Perspectives for systems biology in the management of tuberculosis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Advances in Aptamer-Based Biomarker Discovery.Frontiers in cell and developmental biology · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Payam NahidPulmonary and Critical Care Medicine, University of California, San Francisco at San Francisco General Hospital, 1001 Potrero Ave, 5K1, San Francisco, CA 94110, USA. Electronic address: pnahid@ucsf.edu.
Erin Bliven-SizemoreCenters for Disease Control and Prevention, Division of Tuberculosis Elimination, 1600 Clifton Rd., NE, MS E10, Atlanta, GA 30333, USA.
Leah G JarlsbergPulmonary and Critical Care Medicine, University of California, San Francisco at San Francisco General Hospital, 1001 Potrero Ave, 5K1, San Francisco, CA 94110, USA.
Mary A De GrooteDepartment of Microbiology, Immunology and Pathology, Colorado State University, Campus Box 1682, Fort Collins, CO 80523, USA; SomaLogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, USA.
John L JohnsonTuberculosis Research Unit, Division of Infectious Diseases, Case Western Reserve University, Cleveland, OH, USA; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
Grace MuzanyiUganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
Melissa EngleDepartment of Medicine, Division of Infectious Diseases, University of Texas Health Science Center, San Antonio, TX, USA.
Marc WeinerDepartment of Medicine, Division of Infectious Diseases, University of Texas Health Science Center, San Antonio, TX, USA.
Nebojsa JanjicSomaLogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, USA.
David G SterlingSomaLogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, USA.
Urs A OchsnerSomaLogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, USA. Electronic address: uochsner@somalogic.com.

Funding

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)R01AI104589 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAHID, PAYAM, SIGAL, GEORGE B · 2013 to 2017
$6.2M
NIAID NIH HHS 1R01AI104589NIAID NIH HHS R01 AI104589
6 · The paper itself

Abstract

backgroundNew drug regimens of greater efficacy and shorter duration are needed for tuberculosis (TB) treatment. The identification of accurate, quantitative, non-culture based markers of treatment response would improve the efficiency of Phase 2 TB drug testing.

methodsIn an unbiased biomarker discovery approach, we applied a highly multiplexed, aptamer-based, proteomic technology to analyze serum samples collected at baseline and after 8 weeks of treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in a Centers for Disease Control and Prevention (CDC) TB Trials Consortium Phase 2B treatment trial.

resultsWe identified protein expression differences associated with 8-week culture status, including Coagulation Factor V, SAA, XPNPEP1, PSME1, IL-11 Rα, HSP70, Galectin-8, α2-Antiplasmin, ECM1, YES, IGFBP-1, CATZ, BGN, LYNB, and IL-7. Markers noted to have differential changes between responders and slow-responders included nectin-like protein 2, EphA1 (Ephrin type-A receptor 1), gp130, CNDP1, TGF-b RIII, MRC2, ADAM9, and CDON. A logistic regression model combining markers associated with 8-week culture status revealed an ROC curve with AUC = 0.96, sensitivity = 0.95 and specificity = 0.90. Additional markers showed differential changes between responders and slow-responders (nectin-like protein), or correlated with time-to-culture-conversion (KLRK1).

conclusionsSerum proteins involved in the coagulation cascade, neutrophil activity, immunity, inflammation, and tissue remodeling were found to be associated with TB treatment response. A quantitative, non-culture based, five-marker signature predictive of 8-week culture status was identified in this pilot study.

Indexed as

AdultAntitubercular AgentsBacterial ProteinsBiomarkersDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPilot ProjectsProspective StudiesProteomicsSELEX Aptamer TechniqueTreatment OutcomeTuberculosis, PulmonaryYoung AdultAntitubercular AgentsBacterial ProteinsBiomarkersBiomarkersLogistic regression modelMultiplex analysisProteomicsSOMAscanTreatment responseTuberculosis

Identifiers

PMID24629635
PMCPMC4028389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.